GDNF receptor
US6504007B1 · kind B1 · utility
0Cited by
1References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 6, 1997 |
| Grant date | Jan 7, 2003 |
| Priority date | — |
| Expiry date | Jun 6, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
GDNFR&agr;, GDNFR&agr; extracellular domain (ECD), GDNFR&agr; variants, chimeric GDNFRae (e.g., GDNFR&agr; immunoadhesin), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to GDNFR&agr;-ligands, for example GDNF, by providing GDNFR&agr; to the cell. Also provided are methods for using GDNFR&agr;, GDNF, or agonists thereof, separately or in complex, to treat kidney diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.